Education
About Us
Working with TipRanks
Follow Us
GRAIL Inc (GRAL)
NASDAQ:GRAL
Earnings Data
Report Date
Aug 19, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-3.71Last Year’s EPS
-51.06Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -10.45%
|Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment|Positive
The earnings call presented strong first-quarter results with significant revenue growth and positive trial results, alongside strategic partnerships and market expansion. However, concerns about future funding and uncertainty around key trial results present challenges.Company Guidance
During the GRAIL First Quarter 2025 earnings call, the company provided guidance highlighting several key metrics and achievements. GRAIL reported a revenue of $31.8 million, a 19% increase compared to the previous year, with screening revenue at $29.1 million, up 24%. The company sold over 37,000 Galleri tests in the first quarter and noted that more than 325,000 tests have been prescribed since its 2021 launch. The NHS-Galleri trial demonstrated a higher positive predictive value (PPV) than the 43% observed in the PATHFINDER study. GRAIL's specificity was reported at 99.5% with a cancer signal origin (CSO) accuracy of 88%. The company is on track for a cash burn of no more than $320 million for the year, representing a 40% decrease from 2024, and maintains a cash position of $677.9 million, projecting a runway into 2028. GRAIL anticipates completing its PMA submission to the FDA in the first half of 2026, with final results from the NHS-Galleri trial expected mid-2026.Positive Top-Line Results from NHS-Galleri Trial
The prevalent round of screening in the 140,000 participant NHS-Galleri trial showed strong Galleri performance in detecting multiple types of cancers with very low false positive rates.
Galleri Test Commercial Performance
GRAIL sold more than 37,000 Galleri tests in the first quarter, with over 325,000 tests prescribed by more than 14,000 healthcare providers since its launch in 2021.
Revenue Growth
First quarter revenue was $31.8 million, up 19% compared to the first quarter of 2024. Screening revenue was $29.1 million, up 24% year-over-year.
Cash Runway and Financial Management
GRAIL ended the quarter with a cash position of $677.9 million, with a cash burn for 2025 expected to be no more than $320 million, extending the runway into 2028.
Partnerships and Market Expansion
New partnerships with Athena Health and Quest Diagnostics are streamlining Galleri test ordering, and commercial launch in Israel has begun in partnership with OncoTest.
High Specificity and Positive Predictive Value
Galleri demonstrated a specificity of 99.5% and a positive predictive value higher than 43%, as observed in the PATHFINDER study.
GRAL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GRAL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $42.89 | $32.89 | -23.32% |
Feb 20, 2025 | $47.76 | $40.73 | -14.72% |
Nov 12, 2024 | $15.09 | $15.92 | +5.50% |
Aug 13, 2024 | $15.84 | $15.39 | -2.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does GRAIL Inc (GRAL) report earnings?
GRAIL Inc (GRAL) is schdueled to report earning on Aug 19, 2025, TBA Not Confirmed.
What is GRAIL Inc (GRAL) earnings time?
GRAIL Inc (GRAL) earnings time is at Aug 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GRAL EPS forecast?
GRAL EPS forecast for the fiscal quarter 2025 (Q2) is -3.71.